Vertex Q2 revenue rises 12% to $3.33 billion; raises 2026 revenue guidance
Vertex reported second quarter 2026 results on August 3, 2026, with total revenue of $3.33 billion, up 12% from the prior-year quarter, and GAAP net income of $1.1 billion. The company raised its full-year 2026 total revenue guidance, and it also announced a pending acquisition of Crinetics Pharmaceuticals for $85.00 per share in cash, expected to close in the third quarter of 2026, which is not reflected in its guidance.
Key points
- Q2 2026 total revenue was $3.33 billion, up from $2.96 billion in Q2 2025; GAAP net income was $1.10 billion, up from $1.03 billion.
- GAAP diluted earnings per share were $4.31, compared with $3.99 a year earlier.
- Full-year 2026 total revenue guidance was raised to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion.
- Vertex will acquire Crinetics for $85.00 per share in cash, a total equity value of about $10.0 billion, with closing expected in the third quarter of 2026.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.